Aspen Neuroscience, Inc. announced that Lisa Johnson-Pratt, MD has joined the company's executive management team in a new role as Senior Vice President, Therapeutic Program Lead. An industry leader with more than 25 years of experience, Dr. Johnson-Pratt will guide therapeutic development for ANPD001, the first autologous neuron replacement to treat Parkinson's disease (PD), and new product strategy for Aspen. A senior drug development, clinical and commercial expert, Lisa has successfully led programs across the entire product life cycle, including in medical affairs, clinical development, product development, portfolio planning and new product strategy for organizations from small biotechs to large pharmaceutical companies, including as the Global Dermatology Portfolio Leader, for Merck, head of Global Commercial Pharma Centers of Excellence and head of Early Pipeline Commercial Strategy for GSK, and the head of New Product Strategy for Akcea Therapeutics and Ionis Pharmaceuticals.

Lisa is a board director at Assembly Bio and Tracon Pharma, and is the board chair of Young People in Recovery. Dr. Johnson-Pratt received her Bachelor of Science and Doctor of Medicine degrees from Howard University, with further post-doctoral training in Internal Medicine, Clinical Pharmacology and Pharmaceutical Medicine.